ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Up 71.2% in November

ABIVAX Société Anonyme (NASDAQ:ABVX) was the recipient of a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 484,900 shares, a growth of 71.2% from the November 15th total of 283,200 shares. Currently, 0.9% of the company’s shares are short sold. Based on an average daily volume of 117,700 shares, the short-interest ratio is currently 4.1 days.

ABIVAX Société Anonyme Price Performance

Shares of ABIVAX Société Anonyme stock opened at $7.11 on Friday. ABIVAX Société Anonyme has a 1 year low of $7.11 and a 1 year high of $17.02. The firm has a fifty day moving average price of $9.46 and a 200 day moving average price of $11.34.

Institutional Investors Weigh In On ABIVAX Société Anonyme

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 Asset Management L.P. grew its holdings in ABIVAX Société Anonyme by 28.2% in the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after purchasing an additional 119,300 shares during the period. abrdn plc grew its holdings in shares of ABIVAX Société Anonyme by 167.7% during the third quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after buying an additional 198,225 shares in the last quarter. Walleye Capital LLC raised its holdings in ABIVAX Société Anonyme by 45.8% in the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after acquiring an additional 80,807 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after buying an additional 5,900 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. JMP Securities assumed coverage on shares of ABIVAX Société Anonyme in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $33.00 price objective for the company. Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, ABIVAX Société Anonyme presently has an average rating of “Buy” and a consensus price target of $38.67.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.